According to a study published by the Israelis, the efficacy data for the Pfizer-BioNtech vaccine is rather encouraging for people who received the serum.
Very good efficiency
The Hebrew state is leading the vaccination campaign against Covid-19. The injections were administered on December 19, because the government had previously ordered a large quantity of doses of vaccines developed by the Pfizer / BioNtech duo. In return, the country agrees to provide biomedical data on the effects of this vaccine. Indeed, more than 4.3 million people have already received at least one dose in the country, thanks to the Pfizer-BioNtech vaccine, out of 9.2 million inhabitants. Of these people, 2.88 million received a second injection. According to the Israel Ministry of Health, the vaccine is very effective, allowing 95.8% of immune people to avoid being infected with Sars-Cov-2. That’s not all, since it prevents severe forms of the disease 99.2% and 98.9% to prevent death.
Positive effects from the first dose
According to statistics provided by Israel, the vaccine would be effective from the first dose administered. Contamination with the new coronavirus is avoided for 96.4% of patients who received a single dose. In addition, the latter makes it possible to prevent the appearance of a severe form of the pathology for 96.4% of them, but also to prevent death for 94.5%. The effects are therefore very encouraging for the Pfizer-BioNtech vaccine.
Israel has more than 760,000 cases of Sars-Cov-2 infection and has nearly 5,700 deaths. As the director general of the ministry said in a statement, “ Our goal is to continue immunizing the entire population aged 16 and over. (…) Which will allow us to regain our habits “.
The mRNA vaccine
As a reminder, the vaccine developed by the American and German duo is a messenger RNA vaccine, also called ” nucleic acid vaccine “. This is the first time in the history of vaccination that a laboratory has succeeded in obtaining approval from health authorities for this technology. The main obstacle that scientists encountered was that the RNA molecules were too large. Pfizer-BioNtech, but also Moderna, have succeeded in finding a solution, thanks to the use of nanolipid particles, in particular to transport the vaccine RNA to the cells. However, this is the result of decades of medical research. With the pandemic, the development of this type of vaccine has accelerated considerably.